EUVIMEDEUVIMED entdecken
Crossref

A Standardised Validation Framework for Commercial Antibodies Across Immunodetection Platforms

Steven Xia

Bioscience Biotechnology Research Communications · 25.03.2026 · 19 (1) · 31-37

DOI: 10.21786/bbrc/19.1.4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioscience Biotechnology Research Communications, online erschienen am 30.03.2026. Verfasst von Steven Xia.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibodies are essential tools in biomedical research and clinical investigations, yet variability in specificity, sensitivity, and reproducibility across immunodetection platforms continues to compromise data reliability. Platform-dependent performance differences contribute significantly to reproducibility concerns in life sciences research. This study aimed to develop a standardised cross-platform validation framework for commercial monoclonal antibodies to enable objective performance comparisons and reduce the risk of reproducibility issues. Five clinically relevant protein biomarkers were evaluated using two monoclonal antibodies per target. Antibody performance was assessed across Western blot, immunohistochemistry, and enzyme-linked immunosorbent assay platforms under controlled laboratory conditions. Six validation parameters were measured: specificity, sensitivity, signal-to-noise ratio, cross-reactivity, lot-to-lot consistency, and intra-assay reproducibility. A weighted scoring model was developed to generate a unified validation index. Antibody performance differed significantly between platforms. Some antibodies demonstrated high specificity in Western blot but reduced reliability in immunohistochemistry or ELISA. The weighted scoring framework enabled objective cross-platform comparison and identified antibodies with stable multi-assay reliability. A structured validation strategy improves antibody selection, reduces variability, and strengthens reproducibility in biomedical research. Importantly, this approach supports reproducibility at both experimental and institutional levels. Laboratories adopting structured validation criteria can improve antibody selection, reduce failed experiments, and increase confidence in published findings. The framework is adaptable and can be expanded to include additional validation dimensions such as genetic knockout controls or orthogonal proteomic confirmation. In conclusion, implementing a standardised cross-platform validation strategy enhances antibody reliability, reduces reproducibility risk, and supports more consistent immunodetection across biomedical research applications. Broader adoption of structured validation frameworks may contribute to improved scientific rigour and greater translational confidence in antibody-based investigations.

Zitieren

APA

Xia, S. (2026). A Standardised Validation Framework for Commercial Antibodies Across Immunodetection Platforms. Bioscience Biotechnology Research Communications, 19(1), 31-37. https://doi.org/10.21786/bbrc/19.1.4

Vancouver

Xia S. A Standardised Validation Framework for Commercial Antibodies Across Immunodetection Platforms. Bioscience Biotechnology Research Communications. 2026;19(1):31-37. doi:10.21786/bbrc/19.1.4

BibTeX
@article{Xia2026,
  author = {Xia, Steven},
  title = {A Standardised Validation Framework for Commercial Antibodies Across Immunodetection Platforms},
  journal = {Bioscience Biotechnology Research Communications},
  year = {2026},
  volume = {19},
  number = {1},
  pages = {31--37},
  doi = {10.21786/bbrc/19.1.4}
}
Kostenlos starten →